G
Gian Matteo Rigolin
Researcher at University of Ferrara
Publications - 169
Citations - 4858
Gian Matteo Rigolin is an academic researcher from University of Ferrara. The author has contributed to research in topics: Chronic lymphocytic leukemia & IGHV@. The author has an hindex of 35, co-authored 151 publications receiving 4210 citations. Previous affiliations of Gian Matteo Rigolin include King's College London.
Papers
More filters
Journal ArticleDOI
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure.
Marco Valgimigli,Gian Matteo Rigolin,Alessandro Fucili,Matteo G. Della Porta,Olga Soukhomovskaia,Patrizia Malagutti,Anna Maria Bugli,Letizia Zenone Bragotti,Gloria Francolini,Endri Mauro,Gianluigi Castoldi,Roberto Ferrari +11 more
TL;DR: CD34+ cells and EPC mobilization occurs in HF and shows a biphasic response, with elevation and depression in the early and advanced phases, respectively, which could be related to the myelosuppressive role of TNF-&agr;.
Journal ArticleDOI
Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile
Marco Valgimigli,Gian Matteo Rigolin,Corrado Cittanti,Patrizia Malagutti,Salvatore Curello,Gianfranco Percoco,Anna Maria Bugli,Matteo G. Della Porta,Letizia Zenone Bragotti,L. Ansani,Endri Mauro,Arnalda Lanfranchi,Melchiore Giganti,Luciano Feggi,Gianluigi Castoldi,Roberto Ferrari +15 more
TL;DR: G-CSF administration in acute MI patients was feasible and did not lead to any clinical or angiographic adverse events and resulted in CD34(+) and CD34 (+)AC133(+)VEGFR2(+) cell mobilization.
Journal ArticleDOI
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Lydia Scarfò,Thomas Chatzikonstantinou,Gian Matteo Rigolin,Giulia Quaresmini,Marina Motta,Candida Vitale,José A. García-Marco,Jose Angel Hernandez-Rivas,Fatima Miras,Mónica Baile,Juan Marquet,Carsten Utoft Niemann,Gianluigi Reda,Talha Munir,Eva Gimeno,Monia Marchetti,Francesca Maria Quaglia,Marzia Varettoni,Julio Delgado,Sunil Iyengar,Ann Janssens,Roberto Marasca,Angela Ferrari,Carolina Cuéllar-García,Gilad Itchaki,Martin Spacek,Lorenzo De Paoli,Luca Laurenti,Mark-David Levin,Enrico Lista,Francesca Romana Mauro,Martin Simkovic,Ellen van der Spek,Elisabeth Vandenberghe,Livio Trentin,Ewa Wasik-Szczepanek,Rosa Ruchlemer,Dominique Bron,Maria Rosaria De Paolis,Giovanni Del Poeta,Lucia Farina,Myriam Foglietta,Massimo Gentile,Yair Herishanu,Tobias Herold,Ozren Jakšić,Arnon P. Kater,Sabina Kersting,Lara Malerba,Lorella Orsucci,Viola Maria Popov,Paolo Sportoletti,Mohamed A. Yassin,Barbara Pocali,Gábor Barna,Annalisa Chiarenza,Gimena Dos Santos,Eugene Nikitin,Martin Andres,Maria Dimou,Michael Doubek,Alicia Enrico,Yervand K Hakobyan,Olga Kalashnikova,Macarena Ortiz Pareja,Maria Papaioannou,Davide Rossi,Nimish Shah,Amit Shrestha,Oana Stanca,Niki Stavroyianni,Vladimir Strugov,Constantine S. Tam,Mihnea Zdrenghea,Marta Coscia,Kostas Stamatopoulos,Giuseppe Rossi,Alessandro Rambaldi,Emili Montserrat,Robin Foà,Antonio Cuneo,Paolo Ghia +81 more
TL;DR: In CLL, COVID-19 severity increases with age; antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
Journal ArticleDOI
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Davide Rossi,Lodovico Terzi-di-Bergamo,Lorenzo De Paoli,Michaela Cerri,Guido Ghilardi,Annalisa Chiarenza,Pietro Bulian,Carlo Visco,Francesca Romana Mauro,Fortunato Morabito,Agostino Cortelezzi,Francesco Zaja,Francesco Forconi,Francesco Forconi,Luca Laurenti,Ilaria Del Giudice,Massimo Gentile,Iolanda Vincelli,Marina Motta,Marta Coscia,Gian Matteo Rigolin,Alessandra Tedeschi,Antonino Neri,Roberto Marasca,Omar Perbellini,Carol Moreno,Giovanni Del Poeta,Massimo Massaia,Pier Luigi Zinzani,Marco Montillo,Antonio Cuneo,Valter Gattei,Robin Foà,Gianluca Gaidano +33 more
TL;DR: The majority of very low-risk patients remained free of progression after treatment and their hazard of relapse decreased after 4 years from FCR, indicating that neither the disease nor complications of its treatment affected survival in this favorable CLL group.
Journal ArticleDOI
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes
M.G. Della Porta,Erica Travaglino,Emanuela Boveri,M. Ponzoni,Luca Malcovati,Elli Papaemmanuil,Gian Matteo Rigolin,Cristiana Pascutto,Giorgio Alberto Croci,Umberto Gianelli,Raffaella Milani,Ilaria Ambaglio,Chiara Elena,Marta Ubezio,M C Da Via,Elisa Bono,Daniela Pietra,Federica Quaglia,Raffaella Bastia,Virginia Valeria Ferretti,Antonio Cuneo,E. Morra,Peter J. Campbell,Peter J. Campbell,Attilio Orazi,Rosangela Invernizzi,Mario Cazzola +26 more
TL;DR: A score to define minimal morphological criteria associated to the presence of marrow dysplasia was developed and showed high sensitivity/specificity, acceptable reproducibility and was independently validated.